Search

everythinglearnresearchcommunity

for

Search:↓

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hair follicles for better treatment.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

A 30-year-old man experienced significant hair regrowth and improved libido after using finasteride and dutasteride for androgenetic alopecia, with no adverse effects. He plans to reduce dutasteride dosage when trying to conceive and has been using topical minoxidil since 2015.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

User experienced reduced hair loss with 15mg RU in Serioxyl but had concerning chest pain. Others suggested consulting a doctor or lowering the dose.

The conversation discusses concerns about potential cognitive and emotional effects of finasteride, with the original poster planning to monitor their cognitive performance while using the treatment. A user responds that most people do not experience cognitive shifts, though some report subtle changes.

Gut microbiota significantly influences androgen metabolism, impacting hair loss treatments like finasteride. Probiotics, dietary changes, and fecal microbiota transplants may help manage DHT levels and improve hair health.

A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.

Dutasteride is associated with increased blood glucose, HbA1c, LDL cholesterol, and liver enzyme activity, potentially leading to diabetes, NAFLD, and liver metabolism changes. The conversation highlights concerns about these adverse effects and calls for more studies, including on finasteride.

P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.

The user experienced sexual side effects after starting finasteride and later switched to dutasteride, noticing hormonal changes. They are considering using P5P and possibly aromatase inhibitors to manage high prolactin and estradiol levels.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

A user is curious why their DHT levels are not higher despite using 400mg of testosterone without finasteride, and wonders if zinc or GHK-Cu injections could be influencing this. Another user suggests that more testosterone typically leads to more DHT, but the user might be fortunate not to exceed normal DHT levels.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

Finasteride can quickly raise estradiol levels by blocking DHT, allowing testosterone to convert to estrogen. Taking finasteride for just a few days can affect blood test results.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

A user reports high DHT levels despite taking finasteride and is concerned about inconsistent blood test results. They also take modafinil, vitamin D, and magnesium supplements.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

Hair loss treatments still rely heavily on minoxidil, finasteride, and RU58841, with little innovation. Future treatments like stem cell therapy and RNA technology show promise but are not yet available.

The user experienced hair shedding after starting testosterone replacement therapy (TRT) and is considering using DHT blockers like finasteride or dutasteride to address potential DHT-related hair loss. Low ferritin levels due to frequent blood donations may also contribute to hair issues, and the user is working on stabilizing iron levels.

Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.

User asks if spironolactone can stack with finasteride and pyrilutamide for hair loss treatment. They question why spironolactone is associated with feminizing effects, while RU/pyri/fluridil, which work similarly, are not.

A user experienced mild side effects from 0.5mg finasteride daily, including increased estradiol and minor gynecomastia. They are considering taking a low dose of exemestane to reduce estrogen levels.